Sample6, a Cambridge, MA-based synthetic biology diagnostic company, closed a $12.7m Series C funding.
The round, which brought total investment to date to $32M, was led by Acre Venture Partners, with participation from new investor Valley Oak Investments and existing investors Canaan Partners and Cultivian Sandbox Ventures. In conjunction with the funding, Acre Venture Partner’s Sam Kass joined Sample6’s board.
The company intends to use the funds to commercialize its food pathogen detection system for food safety.
Led by newly appointed CEO Dr. Michael Koeris, Sample6 provides food processors from meat, seafood, dairy, produce, and dry goods with solutions to detect and control pathogens at various points of need in the food chain, allowing them to control their production environments through in-shift testing. Its technology allows testing at the point of need, and complements it with a cloud-based food safety management and control system that can integrate with data from safety and laboratory management systems – including microbial, allergen and other contaminant testing.
Customers include global companies like Unilever, Smithfield, and Saputo amongst others.